Modality
ASO
MOA
PRMT5i
Target
USP1
Pathway
Complement
Melanoma
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
Mar 2021
→ Jan 2026
Phase 1Current
NCT08530078
2,330 pts·Melanoma
2021-03→2026-01·Terminated
2,330 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-192mo agoInterim· Melanoma
2026-12-289mo awayPDUFA· Melanoma
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Termina…
Catalysts
Interim
2026-01-19 · 2mo ago
Melanoma
PDUFA
2026-12-28 · 9mo away
Melanoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08530078 | Phase 1 | Melanoma | Terminated | 2330 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP |